Small molecule prostagladin transport inhibitors

A compound of Formula 1:

• or a pharmaceutically acceptable salt thereof, wherein:
• R1 and R2 are independently chosen from C1-C6alkyl, (C1-C4alkoxy) (C1-C4alkyl), (C3-C7cycloalkyl)C0-C2alkyl, —CO2C1-C6alkyl, and —CO2C0-C2alkyl(C3-C7cycloalkyl), or
• R1 and R2 together may be a 3-6 membered carbocyclic ring or a 4-6-membered heterocycloalkyl ring containing one heteroatom or substituted heteroatom chosen from NH, N—C1-C6alkyl, NCO—C1-C6-alkyl, NCO2—C1-C6-alkyl, NSO2—C1-C6-alkyl, O, S and SO2;
• R3 and R4 are independently chosen from hydrogen, fluoro, and methyl or R3 and R4 can be taken together to form a C3-C5 saturated or partially unsaturated carbocyclic ring or an oxetanyl ring which is optionally 2,2 or 3,3 disubstituted with halogen or C1-C2alkyl;
• A1 is a pyrazinyl or pyrimidinyl heteroarylene group optionally substituted with one or more substituents independently chosen from halogen, hydroxyl, cyano, C1-C6-alkyl, C1-C6alkoxy, (C3-C7-cycloalkyl) C0-C2alkyl, C1-C2haloalkyl, and C1-C2haloalkoxy;
• A2 is —CO2H;
• X1, X2, X3, X4, and X5 are aromatic ring atoms chosen from N and C, where up to 3 of X1, X2, X3, X4, and X5 are N ring atoms and each C ring atom is optionally substituted with R6 where each R6 is independently chosen from halogen, hydroxyl, cyano, amino, —CONH2, C1-C6alkyl, C1-C6alkoxy, C1-C2haloalkyl, C1-C2haloalkoxy, mono- or di-(C1-C6alkylamino) C0-C2alkyl, (C3-C7cycloalkyl) C0-C2alkyl, (C3-C7cycloalkyl) C0-C2alkoxy, (C1-C6alkylSO2) C0-C2alkyl, C1-C6alkylNHCO—, and (C1-C6alkyl)2NCO—;
• and
• Q is absent or is —CH2—, or —CH2CH2—.